



AT A GLANCE

NASDAQ: **GILD**
Founded: **1987**
HQ: **FOSTER CITY, CA**



\$~80B
Market Cap
(as of 4/28/2021)



~13,600
Employees



Presence in
>35 Countries
across
6 Continents

3 Primary Disease Areas:

VIRAL DISEASES

INFLAMMATORY DISEASES

ONCOLOGY

1Q21 FINANCIALS

PRODUCT SALES

\$6.3B

DILUTED NON-GAAP EPS

\$2.08

OPERATING CASH FLOW

\$2.6B

COMMERCIAL PORTFOLIO HIGHLIGHTS

Human Immunodeficiency Virus (HIV)

Treatment



BIKTARVY[®]
bictegravir 50mg/emtricitabine 200mg/
tenofovir alafenamide 25mg tablets



Genvoya[®]
elvitegravir 150mg/cobicistat 150mg/emtricitabine
200mg/tenofovir alafenamide 10mg tablets



Odefsey[®]
emtricitabine 200mg/rilpivirine 25mg/
tenofovir alafenamide 25mg tablets



Descovy[®]
emtricitabine 200mg/
tenofovir alafenamide 25mg tablets

Prevention



Descovy[®]
emtricitabine 200mg/
tenofovir alafenamide 25mg tablets
for **PrEP** pre-exposure prophylaxis



Truvada[®]
emtricitabine 200 mg/tenofovir
disoproxil fumarate 300 mg tablets
for **PrEP** pre-exposure prophylaxis

Oncology



TRODELVY[™]
sacituzumab govitecan-hzyl
180 mg for injection



YESCARTA[™]
(axicabtagene ciloleucel)
Sipuleucel-L



TECARTUS[™]
(brexucabtagene autoleucel)
Sipuleucel-L

Emerging Viruses



Veklury[®]
remdesivir
100 mg FOR INJECTION

Hepatitis C Virus (HCV)



HARVONI[™]
ledipasvir/sofosbuvir
90 mg/400 mg tablets



VOSEVI[™]
sofosbuvir 400mg/velpatasvir 100mg
voixarevir 100mg tablets



EPLUSA[™]
sofosbuvir/velpatasvir
400 mg/100 mg tablets

Hepatitis B Virus (HBV)



Vemlidy[™]
tenofovir alafenamide SODIUM
25mg tablets

ANALYST COVERAGE

Argus, Atlantic Equities, Baird, Bank of America, Barclays, BMO, Cantor Fitzgerald, Citi, Cowen, Evercore ISI, Goldman Sachs, Guggenheim Securities, Jefferies, JPMorgan, Maxim Group, Mizuho, Morgan Stanley, Morningstar, Needham, Oppenheimer, Raymond James, RBC, Redburn, SVB Leerink, Truist, UBS, Wolfe

PIPELINE PRODUCT CANDIDATES

47 Clinical Stage Programs¹ 15 NDA/BLA/MAA filings, P3 and Registrational P2 trials 13 Clinical stage NMEs via in-licensing, and acquisitions accounting for 23 programs 7 Breakthrough Therapy Designations

¹Including in-licensed or acquired programs currently between phase 1 and NDA/BLA/MAA approval. Program count does not include potential opt-in partner programs.

Viral Diseases Pipeline

			Phase 1	Phase 2	Phase 3	Filed
Emerging Viruses	Veklury® (remdesivir injectable form) ¹	COVID-19 outpatient				
	Remdesivir inhaled form (GS-5734)	COVID-19				
HIV	Lenacapavir capsid inhibitor (GS-6207)	HIV LA HTE			Phase 2/3	
		HIV LA VS				
	bNAb combination (GS-5423, GS-2872) ²	HIV Cure				
	Leflotolimod TLR-9 agonist (GS-1703) ²	HIV Cure				
	Vesatolimod TLR-7 agonist (GS-9620)	HIV Cure				
	Elipovimab bNAb (GS-9722)	HIV Cure				
	Unboosted protease inhibitor (GS-1156)	HIV Treatment				
	Long acting bictegravir (GS-9883)	HIV LA				
HBV & HDV	Hepcludex® (bulevirtide) ⁴	HDV				
	Hepcludex® (bulevirtide) + PEG-INF	HDV				
	Selgantolimod TLR-8 agonist (GS-9688)	HBV Cure				
	Oral PD-L1 small molecule (GS-4224)	HBV Cure				

¹Removed from pipeline 12Apr21 ²Non-Gilead sponsored trial(s) ongoing. ³Subject to Gilead and Merck co-development and co-commercialization agreement. ⁴Conditionally approved by the European Medicines Agency (EMA) for the treatment of chronic HDV infection in adults with compensated liver disease in July 2020
bNAb - Broadly neutralizing antibody. EV - Emerging viruses. HTE - Heavily treatment-experienced. LA - Long Acting. VS - Virologically suppressed. Pipeline shown above as of end of Q1'21.

Inflammatory Diseases Pipeline

			Phase 1	Phase 2	Phase 3	Filed
Inflammatory Disease	Filgotinib JAK-1 inhibitor (GS-6034)	Ulcerative colitis				MAA Filed
		Crohn's disease				
	TPL2 inhibitor (GS-5290)	Inflammatory Bowel Disease				
	IRAK4 inhibitor (GS-5718)	Inflammatory Bowel Disease				
		Rheumatoid Arthritis				
Tirabrutintib BTK inhibitor (GS-4059)	CSU					
Fibrotic Disease	Cilofexor FXR agonist (GS-9674)	PSC				
	Cilofexor/firsocostat/semaglutide combination	NASH				
	Selonsertib ASK1 inhibitor (GS-4997)	DKD				
Opt-in programs	Galapagos	Inflammatory and Fibrosis Diseases	8 clinical stage programs			
	Galapagos	Inflammatory and Fibrosis Diseases	Multiple pre-clinical stage programs			

CSU - Chronic Spontaneous Urticaria. DKD - Diabetic kidney disease. IPF - Idiopathic pulmonary fibrosis. NASH - Nonalcoholic steatohepatitis. PSC - Primary sclerosing cholangitis. Pipeline shown above as of end of Q1'21.

Oncology Pipeline

			Phase 1	Phase 2	Phase 3	Filed
Cell Therapy	Yescarta® (Axi-cel)	R/R FL				sBLA Approved
		2L DLBCL				
		1L DLBCL				
	Brexu-cel	Adult ALL			sBLA for AA; Pivotal	
		Pediatric ALL			Pivotal	
	Yescarta® (Axi-cel) ¹	3L DLBCL(+lenzilumab)				
	KITE-718 (MAGE-A3/A6) ²	Solid tumor				
KITE-439 (HPV-16 E7) ²	Solid tumor					

¹Clinical collaboration with Humanigen. Being closed as of 19Apr21. ²Collaboration with NIH.
ALL - Acute lymphocytic leukemia. AML - Acute myeloid leukemia. Axi-cel - Axicabtagene Ciloleuce. Brexu-cel - Brexucabtagene autoleuce. CLL - Chronic lymphocytic leukemia. DLBCL - Diffuse large B cell lymphoma. FL - Follicular lymphoma. HPV-16 E7 - Human papillomavirus-16 E7 protein. MAGE - Melanoma antigen gene. R/R - relapsed / refractory. Pipeline shown above as of end of Q1'21.

Non-Cell Therapy	Trodely™ Sacituzumab govitecan-hziy ¹	mTNBC (2L+)				sBLA Approved; MAA Filed
	Sacituzumab govitecan-hziy (GS-0132)	Urothelial (2L+)				sBLA Approved
	Magrolimab anti-CD47 (GS-4721) ²	MDS				
	Sacituzumab govitecan-hziy (GS-0132)	HR+/HER2-mBC				
	Zimberelimab PD1 (GS-0122) ³	NSCLC				
	Sacituzumab govitecan-hziy (GS-0132)	Basket (incl. NSCLC)				
	Sacituzumab govitecan-hziy (GS-0132) + CPI ³	mTNBC (1L), mUC, mNSCLC			Phase 1b/2	
	Magrolimab anti-CD47 (GS-4721) ⁴	AML			Phase 1b/2	
	Magrolimab anti-CD47 (GS-4721)	DLBCL			Phase 1b/2	
	Sacituzumab govitecan-hziy (GS-0132) + PARPi ³	mTNBC, mUC, Ovarian			Phase 1b/2	
	Oral PD-L1 small molecule inhibitor (GS-4224)	NSCLC				
	Magrolimab anti-CD47 (GS-4721)	Solid tumors		Phase 1b		
	Flt3R agonist (GS-3583)	ONC		Phase 1a		
	Anti-c-KIT (GS-0174)	TCR		Phase 1a		
	Anti-SIRP-α (GS-0189)	ONC		Phase 1a		
Opt-in programs	Arcus	ONC	4 clinical stage programs			
	Agenus	Solid tumors	2 clinical stage programs			
	Tizona	Advanced cancers	1 clinical stage program			
	Pionyr	Solid tumors	2 clinical stage programs			

¹Full FDA approval granted on 07Apr2021. ²FDA accelerated approval granted on 13Apr2021. ³Non-Gilead sponsored trial(s) ongoing. ⁴Additional MDS and AML cohorts within other ongoing Ph 1b study.
AML - Acute myeloid leukemia. CPI - Checkpoint inhibitor. DLBCL - Diffuse large B cell lymphoma. HR+/HER2- mBC - Hormone Receptor positive, human epidermal growth factor receptor 2 negative metastatic breast cancer. MDS - Myelodysplastic syndrome. mTNBC - Metastatic triple-negative breast cancer. mUC - metastatic urothelial cancer. mNSCLC - metastatic non-small cell lung cancer. NSCLC - Non small cell lung cancer. PARPi - PARP inhibitor. TCR - Transplant conditioning regimen. TME - Tumor microenvironment. Pipeline shown above as of end of Q1'21.